Nippon Shinyaku Co Ltd (NPPNY) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Nippon Shinyaku Co Ltd $12.24, price $5.46, upside +124.2%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
Nippon Shinyaku Co Ltd
NPPNY · USClearly undervaluedStrong Fair Value upside, but quality is only moderate.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $3.97 – $19.21 · fair‑value band $8.49 – $17.19 · the $5.46 price screens below the $12.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Every Wednesday you see whether Nippon Shinyaku Co Ltd ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments.
Show more
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Stock analysis
Nippon Shinyaku Co Ltd ADR (NPPNY) currently trades at $5.46, while our model-based Fair Value estimate is $12.24, implying the stock looks roughly 55.4% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $14.02 per share, and 21 of the 24 models we run sit above the $5.46 price.
Bear case: the Asset-Based group reads lowest at $4.52, and 3 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $8.49 (bear) to $17.19 (bull), the price of $5.46 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Nippon Shinyaku Co Ltd ADR reported revenue of ¥181B in FY2026 versus ¥137B in FY2022, a compound +7.1%/yr. Reported net income was ¥31.5B in FY2026, compounding +6.0%/yr from FY2022.
Key figures
Market cap $1.7B · P/E ratio 7.9 · P/S ratio 1.38 · EPS (TTM) $0.6900 · Dividend yield 3.4% · Net margin 17.4% · Return on equity 11.0% · Return on assets (EBIT) 12.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 124%, NPPNY screens cheaper than that median.
Fair Value models
All 24 models by family
Notify me when NPPNY reaches fair value
Put NPPNY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 24
Revenue & earnings trend
Growth Forecast
Watch NPPNY, get fair value alerts →
Earlier news
- NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.
- AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
- Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dy
- Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne
Compare Nippon Shinyaku Co Ltd ADR with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €133.15 | €108.70 | −18% |
| Takeda Pharmaceutical Company TAK | $18.95 | $11.29 | −40% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥45.72 | ¥50.29 | +10% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,846 | ₹1,979 | +7% |
| Galderma Group GALD | CHF 163.80 | CHF 109.88 | −33% |
| Haleon plc HLN | $9.25 | $8.50 | −8% |
| Teva Pharmaceutical Industries Limited TEVA | $39.52 | $20.75 | −47% |
| Sandoz Group SDZ | CHF 70.76 | CHF 40.16 | −43% |
| Zoetis Inc ZTS | $72.86 | $108.48 | +49% |
| Hansoh Pharmaceutical Group 3692 | HK$35.34 | HK$38.87 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Nippon Shinyaku Co Ltd (NPPNY) overvalued or undervalued?
What is the fair value of NPPNY?
What is the quality score of NPPNY?
What is the price target for Nippon Shinyaku Co Ltd (NPPNY)?
What is the Nippon Shinyaku Co Ltd ADR stock forecast for 2026?
What is the revenue of Nippon Shinyaku Co Ltd (NPPNY)?
Does Nippon Shinyaku Co Ltd ADR pay a dividend?
What growth is priced into Nippon Shinyaku Co Ltd (NPPNY)?
What discount rate (WACC) does the fair value of NPPNY use?
What is a reverse DCF?
How much growth has Nippon Shinyaku Co Ltd (NPPNY) delivered so far?
How fast is the sector of Nippon Shinyaku Co Ltd (NPPNY) growing?
What is the free cash flow yield of Nippon Shinyaku Co Ltd (NPPNY)?
What is the intrinsic value of Nippon Shinyaku Co Ltd (NPPNY)?
Is Nippon Shinyaku Co Ltd ADR stock overvalued or undervalued in 2026?
Is fair value the same as the market price of NPPNY?
How much is Nippon Shinyaku Co Ltd ADR worth?
What do the bullish and bearish scenarios say about NPPNY?
What is the P/E ratio of NPPNY?
How solid is the balance sheet of Nippon Shinyaku Co Ltd (NPPNY)?
How far is NPPNY from its 52-week high?
Which stocks are comparable to Nippon Shinyaku Co Ltd ADR?
Is Nippon Shinyaku Co Ltd ADR stock attractive at the current price?
How is the fair value of NPPNY calculated?
Is it still worth investing in stocks now?
What is the share price of Nippon Shinyaku Co Ltd (NPPNY)?
What should I pay attention to with Nippon Shinyaku Co Ltd ADR right now?
Where does the earnings growth of Nippon Shinyaku Co Ltd (NPPNY) come from?
Key figures of Nippon Shinyaku Co Ltd ADR
How large is the market capitalisation of Nippon Shinyaku Co Ltd (NPPNY)?
What is the P/S ratio of Nippon Shinyaku Co Ltd (NPPNY)?
What are the earnings per share of Nippon Shinyaku Co Ltd (NPPNY)?
What is the dividend yield of Nippon Shinyaku Co Ltd (NPPNY)?
What is the net margin of Nippon Shinyaku Co Ltd (NPPNY)?
What is the return on equity of Nippon Shinyaku Co Ltd (NPPNY)?
What is the EBIT return on assets of Nippon Shinyaku Co Ltd (NPPNY)?
What is the operating margin of Nippon Shinyaku Co Ltd (NPPNY)?
How fast is revenue growing at Nippon Shinyaku Co Ltd (NPPNY)?
How fast are earnings growing at Nippon Shinyaku Co Ltd (NPPNY)?
How much net cash does Nippon Shinyaku Co Ltd (NPPNY) hold?
Watch Nippon Shinyaku Co Ltd ADR in the live analysis
One click puts Nippon Shinyaku Co Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.